Arcellx, Inc.
ACLX
株式のランク
#2786
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
株価
$115.07
最終同期: 2026-05-15
時価総額
$6.73B
変化（1日）
0.00%
変化（1年）
32.61%
国
US
取引 Arcellx, Inc. (ACLX)
カテゴリー
Healthcare
Arcellx, Inc.（ACLX）の発行済株式数
December 2025 時点の発行済株式数 56.31M
Arcellx, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 56.31M です。December 2023 の終わりには、同社は 48.06M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Arcellx, Inc.（ACLX）の発行済株式数の履歴（2018 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 56.31M | 5.11% |
| 2024 | 53.57M | 11.45% |
| 2023 | 48.06M | 8.97% |
| 2022 | 44.11M | 31.49% |
| 2021 | 33.54M | 54.04% |
| 2020 | 21.78M | -37.39% |
| 2019 | 34.78M | 20,905.45% |
| 2018 | 165.58K | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 350.93% |
US
|
|
| 396.00M | 603.31% |
US
|
|
| 478.91M | 750.56% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 10.44% |
NL
|
